NeuroSense Therapeutics Ltd (NASDAQ:NRSN), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced on Wednesday that the United States Patent and Trademark Office has granted US Patent No. 12,527,768, entitled 'Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases'.

This patent provides protection for the use of PrimeC combination in Alzheimer's disease, strengthening NeuroSense's intellectual property estate and supporting the programme's long-term development and potential commercialisation, with protection extending until 2043.

Alon Ben-Noon, NeuroSense co-founder and chief executive officer, said: "This patent meaningfully expands and reinforces our intellectual property position around the PrimeC combination. It reflects both the breadth of the underlying biology and our strategy to build durable protection as we advance PrimeC combination clinically in Alzheimer's disease and other neurodegenerative conditions."